Analysts think HROW stock price could increase by 94%
Nov 09, 2025, 12:25 PM
34.76%
What does HROW do
Harrow, headquartered in Nashville, Tennessee, develops and sells innovative ophthalmic medications and operates ImprimisRx, employing 315 staff since its IPO on February 8, 2013. The company markets various prescription products, including VIGAMOX and IHEEZO.
9 analysts think HROW stock price will increase by 93.66%. The current median analyst target is $65.69 compared to a current stock price of $33.92. The lowest analysts target is $63.63 and the highest analyst target is $79.80.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.